BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 21377690)

  • 1. Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder.
    Mota-Pereira J; Silverio J; Carvalho S; Ribeiro JC; Fonte D; Ramos J
    J Psychiatr Res; 2011 Aug; 45(8):1005-11. PubMed ID: 21377690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association between health related quality of life and severity of depression in patients with major depressive disorder].
    Cao Y; Li W; Shen J; Zhang Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 36(2):143-8. PubMed ID: 21368424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder.
    Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A
    Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results.
    Maina G; Rosso G; Bogetto F
    J Affect Disord; 2009 Apr; 114(1-3):200-7. PubMed ID: 18728001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG; Schlaepfer TE; Andersen HF; Kilts CD
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exercise treatment for depression: efficacy and dose response.
    Dunn AL; Trivedi MH; Kampert JB; Clark CG; Chambliss HO
    Am J Prev Med; 2005 Jan; 28(1):1-8. PubMed ID: 15626549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are exercise stress tests appropriate for assessing myocardial ischemia in patients with major depressive disorder?
    Lavoie KL; Fleet RP; Lespérance F; Arsenault A; Laurin C; Frasure-Smith N; Bacon SL
    Am Heart J; 2004 Oct; 148(4):621-7. PubMed ID: 15459592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
    BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.